Selected research
Industry Research
Tumor Detection Services Industry Research Report 2026
Market perspective
The global Tumor Detection Services market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Tumor Detection Services market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Tumor Detection Services market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Tumor Detection Services market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Tumor Detection Services include Nonacus, Natera, Penn Medicine, Amadix, Oncologica, Rarecells, GRAIL, Elypta and Bio-Techne, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Tumor Detection Services market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Tumor Detection Services.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tumor Detection Services Market by Company
Nonacus
Natera
Penn Medicine
Amadix
Oncologica
Rarecells
GRAIL
Elypta
Bio-Techne
iCAD
Dxcover
Caris Life Sciences
Novocure
Circulogene
Guardant Health
Veracyte
Haystack Oncology
Foundation Medicine
Tumor Detection Services Segment by Type
Non-Invasive Examination
Invasive Examination
Tumor Detection Services Segment by Application
Adults
Children
Tumor Detection Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Detection Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Detection Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Detection Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Tumor Detection Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Non-Invasive Examination
- Invasive Examination
Applications
- Adults
- Children
Companies covered
- Nonacus
- Natera
- Penn Medicine
- Amadix
- Oncologica
- Rarecells
- GRAIL
- Elypta
- Bio-Techne
- iCAD
- Dxcover
- Caris Life Sciences
- Novocure
- Circulogene
- Guardant Health
- Veracyte
- Haystack Oncology
- Foundation Medicine
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Tumor Detection Services by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Non-Invasive Examination
- 2.2.3 Invasive Examination
- 2.3 Tumor Detection Services by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Adults
- 2.3.3 Children
- 2.4 Assumptions and Limitations
3 Tumor Detection Services Breakdown Data by Type
- 3.1 Global Tumor Detection Services Historic Market Size by Type (2021-2026)
- 3.2 Global Tumor Detection Services Forecasted Market Size by Type (2027-2032)
4 Tumor Detection Services Breakdown Data by Application
- 4.1 Global Tumor Detection Services Historic Market Size by Application (2021-2026)
- 4.2 Global Tumor Detection Services Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Tumor Detection Services Market Perspective (2021-2032)
- 5.2 Global Tumor Detection Services Growth Trends by Region
- 5.2.1 Global Tumor Detection Services Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Tumor Detection Services Historic Market Size by Region (2021-2026)
- 5.2.3 Tumor Detection Services Forecasted Market Size by Region (2027-2032)
- 5.3 Tumor Detection Services Market Dynamics
- 5.3.1 Tumor Detection Services Industry Trends
- 5.3.2 Tumor Detection Services Market Drivers
- 5.3.3 Tumor Detection Services Market Challenges
- 5.3.4 Tumor Detection Services Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Tumor Detection Services Players by Revenue
- 6.1.1 Global Top Tumor Detection Services Players by Revenue (2021-2026)
- 6.1.2 Global Tumor Detection Services Revenue Market Share by Players (2021-2026)
- 6.2 Global Tumor Detection Services Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Tumor Detection Services Head Office and Area Served
- 6.4 Global Tumor Detection Services Players, Product Type & Application
- 6.5 Global Tumor Detection Services Manufacturers Established Date
- 6.6 Global Tumor Detection Services Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Tumor Detection Services Market Size (2021-2032)
- 7.2 North America Tumor Detection Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Tumor Detection Services Market Size by Country (2021-2026)
- 7.4 North America Tumor Detection Services Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Tumor Detection Services Market Size (2021-2032)
- 8.2 Europe Tumor Detection Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Tumor Detection Services Market Size by Country (2021-2026)
- 8.4 Europe Tumor Detection Services Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Tumor Detection Services Market Size (2021-2032)
- 9.2 Asia-Pacific Tumor Detection Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Tumor Detection Services Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Tumor Detection Services Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Tumor Detection Services Market Size (2021-2032)
- 10.2 South America Tumor Detection Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Tumor Detection Services Market Size by Country (2021-2026)
- 10.4 South America Tumor Detection Services Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Tumor Detection Services Market Size (2021-2032)
- 11.2 Middle East & Africa Tumor Detection Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Tumor Detection Services Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Tumor Detection Services Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Nonacus
- 12.1.1 Nonacus Company Information
- 12.1.2 Nonacus Business Overview
- 12.1.3 Nonacus Revenue in Tumor Detection Services Business (2021-2026)
- 12.1.4 Nonacus Tumor Detection Services Product Portfolio
- 12.1.5 Nonacus Recent Developments
- 12.2 Natera
- 12.2.1 Natera Company Information
- 12.2.2 Natera Business Overview
- 12.2.3 Natera Revenue in Tumor Detection Services Business (2021-2026)
- 12.2.4 Natera Tumor Detection Services Product Portfolio
- 12.2.5 Natera Recent Developments
- 12.3 Penn Medicine
- 12.3.1 Penn Medicine Company Information
- 12.3.2 Penn Medicine Business Overview
- 12.3.3 Penn Medicine Revenue in Tumor Detection Services Business (2021-2026)
- 12.3.4 Penn Medicine Tumor Detection Services Product Portfolio
- 12.3.5 Penn Medicine Recent Developments
- 12.4 Amadix
- 12.4.1 Amadix Company Information
- 12.4.2 Amadix Business Overview
- 12.4.3 Amadix Revenue in Tumor Detection Services Business (2021-2026)
- 12.4.4 Amadix Tumor Detection Services Product Portfolio
- 12.4.5 Amadix Recent Developments
- 12.5 Oncologica
- 12.5.1 Oncologica Company Information
- 12.5.2 Oncologica Business Overview
- 12.5.3 Oncologica Revenue in Tumor Detection Services Business (2021-2026)
- 12.5.4 Oncologica Tumor Detection Services Product Portfolio
- 12.5.5 Oncologica Recent Developments
- 12.6 Rarecells
- 12.6.1 Rarecells Company Information
- 12.6.2 Rarecells Business Overview
- 12.6.3 Rarecells Revenue in Tumor Detection Services Business (2021-2026)
- 12.6.4 Rarecells Tumor Detection Services Product Portfolio
- 12.6.5 Rarecells Recent Developments
- 12.7 GRAIL
- 12.7.1 GRAIL Company Information
- 12.7.2 GRAIL Business Overview
- 12.7.3 GRAIL Revenue in Tumor Detection Services Business (2021-2026)
- 12.7.4 GRAIL Tumor Detection Services Product Portfolio
- 12.7.5 GRAIL Recent Developments
- 12.8 Elypta
- 12.8.1 Elypta Company Information
- 12.8.2 Elypta Business Overview
- 12.8.3 Elypta Revenue in Tumor Detection Services Business (2021-2026)
- 12.8.4 Elypta Tumor Detection Services Product Portfolio
- 12.8.5 Elypta Recent Developments
- 12.9 Bio-Techne
- 12.9.1 Bio-Techne Company Information
- 12.9.2 Bio-Techne Business Overview
- 12.9.3 Bio-Techne Revenue in Tumor Detection Services Business (2021-2026)
- 12.9.4 Bio-Techne Tumor Detection Services Product Portfolio
- 12.9.5 Bio-Techne Recent Developments
- 12.10 iCAD
- 12.10.1 iCAD Company Information
- 12.10.2 iCAD Business Overview
- 12.10.3 iCAD Revenue in Tumor Detection Services Business (2021-2026)
- 12.10.4 iCAD Tumor Detection Services Product Portfolio
- 12.10.5 iCAD Recent Developments
- 12.11 Dxcover
- 12.11.1 Dxcover Company Information
- 12.11.2 Dxcover Business Overview
- 12.11.3 Dxcover Revenue in Tumor Detection Services Business (2021-2026)
- 12.11.4 Dxcover Tumor Detection Services Product Portfolio
- 12.11.5 Dxcover Recent Developments
- 12.12 Caris Life Sciences
- 12.12.1 Caris Life Sciences Company Information
- 12.12.2 Caris Life Sciences Business Overview
- 12.12.3 Caris Life Sciences Revenue in Tumor Detection Services Business (2021-2026)
- 12.12.4 Caris Life Sciences Tumor Detection Services Product Portfolio
- 12.12.5 Caris Life Sciences Recent Developments
- 12.13 Novocure
- 12.13.1 Novocure Company Information
- 12.13.2 Novocure Business Overview
- 12.13.3 Novocure Revenue in Tumor Detection Services Business (2021-2026)
- 12.13.4 Novocure Tumor Detection Services Product Portfolio
- 12.13.5 Novocure Recent Developments
- 12.14 Circulogene
- 12.14.1 Circulogene Company Information
- 12.14.2 Circulogene Business Overview
- 12.14.3 Circulogene Revenue in Tumor Detection Services Business (2021-2026)
- 12.14.4 Circulogene Tumor Detection Services Product Portfolio
- 12.14.5 Circulogene Recent Developments
- 12.15 Guardant Health
- 12.15.1 Guardant Health Company Information
- 12.15.2 Guardant Health Business Overview
- 12.15.3 Guardant Health Revenue in Tumor Detection Services Business (2021-2026)
- 12.15.4 Guardant Health Tumor Detection Services Product Portfolio
- 12.15.5 Guardant Health Recent Developments
- 12.16 Veracyte
- 12.16.1 Veracyte Company Information
- 12.16.2 Veracyte Business Overview
- 12.16.3 Veracyte Revenue in Tumor Detection Services Business (2021-2026)
- 12.16.4 Veracyte Tumor Detection Services Product Portfolio
- 12.16.5 Veracyte Recent Developments
- 12.17 Haystack Oncology
- 12.17.1 Haystack Oncology Company Information
- 12.17.2 Haystack Oncology Business Overview
- 12.17.3 Haystack Oncology Revenue in Tumor Detection Services Business (2021-2026)
- 12.17.4 Haystack Oncology Tumor Detection Services Product Portfolio
- 12.17.5 Haystack Oncology Recent Developments
- 12.18 Foundation Medicine
- 12.18.1 Foundation Medicine Company Information
- 12.18.2 Foundation Medicine Business Overview
- 12.18.3 Foundation Medicine Revenue in Tumor Detection Services Business (2021-2026)
- 12.18.4 Foundation Medicine Tumor Detection Services Product Portfolio
- 12.18.5 Foundation Medicine Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst